KLRK1 and breast cancer: In addition, the expression of activating NK cell receptors (such as NKp30, NKG2D, DNAM‐1, and CD16) decreased while inhibitory receptors (e.g., NKG2A) increased, related to impaired NK cell activity in breast cancer.96